CardioGenics(OTC) CGNH

Market Cap$12.00K

Since IPO (2009)-100%

5 Year-100%

1 Year+9,900%

1 Month+9,900%

$0.00

+0.00%

+0.00Today

CardioGenics last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-26

CardioGenics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-10
1 month	+9,900%	USD 0.00	2026-07-17
3 month	+0%	USD 0.00	2026-04-28
Year to date	+9,900%	USD 0.00	2025-12-31
1 year	+9,900%	USD 0.00	2025-08-12
3 year	+0%	USD 0.00	2023-08-17
5 year	-99.79%	USD 0.05	2021-08-27
Since inception	-100%	USD 4.20	2009-08-03

CardioGenics Financials at a Glance

Market Cap

$12.00K

Revenue (TTM)

$0.00

Net Income (TTM)

-$980.79K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-30.19 (Low)

Dividend

$0.00

Beta (Volatility)

-30.19 (Low)

Price

$0.00

Volume

2,500

Open

$0.00

Price

$0.00

Volume

2,500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2016

Dividend

$0.00

Beta (Volatility)

-30.19 (Low)

Price

$0.00

Volume

2,500

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 26, 2016

CGNH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CardioGenics

CardioGenics Holdings Inc. specializes in the development and global distribution of diagnostic testing solutions in the in vitro diagnostics (IVD) sector. The company offers innovative products aimed at improving patient care through rapid and accurate diagnostic testing.

Products and Services

QL Care Analyzer, a portable point-of-care immunoassay device
Immunoassay panels for detecting cardiac biomarkers in blood
Paramagnetic beads for heterogeneous immunoassay procedures

Growth Outlook

Expansion into international markets, including Europe and Canada
Increasing demand for rapid diagnostic solutions in healthcare
Focus on innovative product development to enhance market presence

Financial Highlights

Recent quarterly net income of -$125,292, indicating ongoing operational challenges
Trailing twelve months (TTM) revenue remains at $0, reflecting early-stage development
Cash and cash equivalents of $96,810, providing liquidity for operations

CardioGenics Holdings Inc. is positioned within the healthcare sector, specifically in medical diagnostics and research. The company has developed the QL Care Analyzer, which is a significant advancement in point-of-care testing, allowing for immediate results in critical situations. This technology is particularly relevant in emergency medical settings where timely diagnosis can significantly impact patient outcomes. Despite facing financial challenges, including a recent net loss, the company is focused on expanding its product offerings and market reach. The demand for rapid diagnostic solutions is on the rise, driven by the need for efficient healthcare delivery. CardioGenics aims to leverage this trend by enhancing its product line and exploring new markets. The financial data indicates that while the company has not yet generated revenue, it maintains a modest cash reserve, which is crucial for sustaining operations and funding future growth initiatives. Investors may find interest in the potential for innovation and market expansion as CardioGenics continues to develop its diagnostic solutions.

AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Mississauga, ON L4V 1W8, CA

CGNH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

141.01%

Return on Capital

N/A

Return on Assets

-826.24%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.00K

Shares Outstanding

120.23M

Volume

2.50K

Avg. Volume

2.01K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$767.54K

EBITDA

-$753.55K

Operating Cash Flow

-$366.41K

Capital Expenditure

$0.00

Free Cash Flow

-$366.41K

Cash & ST Invst.

$96.81K

Total Debt

$378.50K

CardioGenics Performance Analysis

CardioGenics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2015-04-30	N/A
Q3	2015-07-31	N/A
Q4	2015-10-31	N/A
Q1	2016-01-31	N/A

CardioGenics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2015-04-30	108.4%
Q3	2015-07-31	-616.7%
Q4	2015-10-31	50.0%
Q1	2016-01-31	64.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2016YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$12.00K

N/A

Market Cap/Employee

$3.00K

N/A

Employees

N/A

Net Income

-$125.29K

+88.2%

EBITDA

-$197.51K

+1.9%

Quarterly Fundamentals

Name

Q1 2016YOY CHG

Total Cash

$96.81K

+14.4%

Total Debt

$378.50K

+321.4%

Accounts Receivable

$0.00

N/A

Inventory

-$385.10K

-12651.7%

Long Term Debt

$0.00

N/A

Short Term Debt

$378.50K

+321.4%

Return on Assets

-8.26%

N/A

Return on Invested Capital

49.40%

N/A

Free Cash Flow

$30.06K

+114.3%

Operating Cash Flow

$30.06K

+114.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FPMIFluoroPharma Medical, Inc.

FPMIFluoroPharma Medical, Inc.$0.00+0.00%

PFNDPathfinder Cell Therapy, Inc.

PFNDPathfinder Cell Therapy, Inc.$0.00+0.00%

BZYRBurzynski Research Institute, Inc.

BZYRBurzynski Research Institute, Inc.$0.01-44.44%

QGENQiagen N.V.

QGENQiagen N.V.$43.29+0.42%

CRLCharles River Laboratories International, Inc.

CRLCharles River Laboratories International, Inc.$288.24-1.12%

IDXXIDEXX Laboratories, Inc.

IDXXIDEXX Laboratories, Inc.$556.69+0.31%

TMOThermo Fisher Scientific Inc.

TMOThermo Fisher Scientific Inc.$617.10-0.82%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About CGNH

What is the current price of CardioGenics?

CardioGenics is trading at $0.00 per share.

What is the 52-week range for CardioGenics?

Over the past 52 weeks, CardioGenics has traded between $0.00 and $0.00.

How much debt does CardioGenics have?

CardioGenics total debt is unavailable.

How much cash does CardioGenics have on hand?

CardioGenics does not have cash on hand data available.

What is CardioGenics’s dividend yield?

CardioGenics does not currently have a dividend yield.

CardioGenics(OTC) CGNH

CardioGenics Financials at a Glance

CGNH News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About CardioGenics

CGNH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

CardioGenics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CGNH

What is the current price of CardioGenics?

What is the 52-week range for CardioGenics?

How much debt does CardioGenics have?

How much cash does CardioGenics have on hand?

What is CardioGenics’s dividend yield?

Premium Investing Services